BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENHERTU (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate combining a humanized anti-HER2 IgG1 with a topoisomerase I inhibitor payload (DXd). It treats HER2-positive and HER2-low metastatic breast cancer, as well as adjuvant and neoadjuvant settings, by delivering cytotoxic cargo intracellularly following HER2 binding and internalization.
$0.01BPart D
PeakENHERTU is in peak commercial phase with moderate competitive pressure (score: 30/100), indicating mature market positioning and stable, specialized team requirements.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Castrate Resistant Prostate Cancer Enhertu Therapy
Started Mar 2025
60 enrolled
Prostate Cancer MetastaticProstate CancerCRPC
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
Started Feb 2025
260 enrolled
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Started Jul 2023
1 enrolled
Esophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more
Worked on ENHERTU at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.